<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The goals of <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) and <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> (AFL) <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> management are to alleviate patient symptoms, improve patient quality of life, and minimize the morbidity associated with AF and AFL </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011675'>Arrhythmia</z:hpo> management usually commences with drugs to slow the ventricular rate </plain></SENT>
<SENT sid="2" pm="."><plain>The addition of class I or class III antiarrhythmic drugs for restoration or maintenance of sinus rhythm is largely determined by patient symptoms and preferences </plain></SENT>
<SENT sid="3" pm="."><plain>For rate control, treatment of persistent or permanent AF and AFL should aim for a resting heart rate of &lt;100 beats per minute </plain></SENT>
<SENT sid="4" pm="."><plain>Beta-blockers or nondihydropyridine <z:chebi fb="0" ids="38215">calcium channel blockers</z:chebi> are the initial therapy for rate control of AF and AFL in most patients without a history of <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> or left ventricular dysfunction </plain></SENT>
<SENT sid="5" pm="."><plain>Digoxin is not recommended as monotherapy for rate control in active patients </plain></SENT>
<SENT sid="6" pm="."><plain>Digoxin and <z:chebi fb="0" ids="50659">dronedarone</z:chebi> may be used in combination with other agents to optimize rate control </plain></SENT>
<SENT sid="7" pm="."><plain>The first-choice antiarrhythmic drug for maintenance of sinus rhythm in patients with non structural <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> can be any one of <z:chebi fb="0" ids="50659">dronedarone</z:chebi>, flecainide, propafenone, or sotalol </plain></SENT>
<SENT sid="8" pm="."><plain>In patients with abnormal ventricular function but left ventricular ejection fraction &gt;35%, <z:chebi fb="0" ids="50659">dronedarone</z:chebi>, sotalol, or <z:chebi fb="0" ids="2663">amiodarone</z:chebi> is recommended </plain></SENT>
<SENT sid="9" pm="."><plain>In patients with left ventricular ejection fraction &lt;35%, <z:chebi fb="0" ids="2663">amiodarone</z:chebi> is the only drug usually recommended </plain></SENT>
<SENT sid="10" pm="."><plain>Intermittent antiarrhythmic drug therapy ("pill in the pocket") may be considered in symptomatic patients with infrequent, longer-lasting episodes of AF or AFL as an alternative to daily antiarrhythmic therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Referral for ablation of AF may be considered for patients who remain symptomatic after adequate trials of antiarrhythmic drug therapy and in whom a rhythm control strategy remains desired </plain></SENT>
</text></document>